ZEMAIRA Drug Profile

Summary for Tradename: ZEMAIRA

High Confidence Patents:	28
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ZEMAIRA

Recent Clinical Trials for ZEMAIRA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Inhibrx, Inc.	Phase 2
Children's Hospital Medical Center, Cincinnati	Phase 2
National Institutes of Health (NIH)	Phase 2

See all ZEMAIRA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZEMAIRA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZEMAIRA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Csl Behring Llc	ZEMAIRA	alpha-1-proteinase inhibitor (human)	For Injection	125078	10,098,950	2037-09-15	DrugPatentWatch analysis and company disclosures
Csl Behring Llc	ZEMAIRA	alpha-1-proteinase inhibitor (human)	For Injection	125078	10,179,183	2037-05-30	DrugPatentWatch analysis and company disclosures
Csl Behring Llc	ZEMAIRA	alpha-1-proteinase inhibitor (human)	For Injection	125078	10,179,184	2034-11-25	DrugPatentWatch analysis and company disclosures
Csl Behring Llc	ZEMAIRA	alpha-1-proteinase inhibitor (human)	For Injection	125078	10,376,571	2034-03-14	DrugPatentWatch analysis and company disclosures
Csl Behring Llc	ZEMAIRA	alpha-1-proteinase inhibitor (human)	For Injection	125078	10,675,376	2033-03-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ZEMAIRA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for ZEMAIRA

Country	Patent Number	Estimated Expiration
Australia	2007200030
Canada	3036251
European Patent Office	3288607
European Patent Office	2328602
Lithuania	PA2018003

Supplementary Protection Certificates for ZEMAIRA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
323 2-2018	Slovakia		PRODUCT NAME: BRODALUMAB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1155/001 - EU/1/16/1155/002 20170719
LUC00056	Luxembourg		PRODUCT NAME: AN ISOLATED ANTIBODY OR FRAGMENT THEREOF COMPRISING LIGHT CHAIN AND HEAVY CHAIN CDR SEQUENCES ACCORDING TO EP-B1-2076541 CLAIM 1 (SEQ ID NOS: 224,225,226 AND 146, 147, 148), WHEREIN THE ANTIBODY OR FRAGMENT THEREOF BINDS HUMAN IL-17 RECEPTOR A; ESPECIALLY AN ANTIBODY COMPRISING THE LIGHT AND HEAVY CHAIN VARIABLE REGION SEQUENCES ACCORDING TO EP-B1-2076541 CLAIM 2 (SEQ ID NOS: 40 AND 14), SUCH AS AN IGG2 ANTIBODY COMPRISING THE LIGHT AND HEAVY CHAIN VARIABLE REGION SEQUENCES ACCORDING TO EP-B1-2076541 CLAIM 2 (SEQ ID NOS: 40 AND 14); AND SPECIFICALLY BRODALUMAB; AND ITS DERIVATES PROTECTED BY EP-B1-2076541; AUTHORISATION NUMBER AND DATE: EU/1/16/1155/001-002 20170719
2018/003	Ireland		PRODUCT NAME: BRODALUMAB; REGISTRATION NO/DATE: EU/1/16/1155/001-002 20170717
PA2018003	Lithuania		PRODUCT NAME: ISSKIRTAS AB ARBA JO FRAGMENTAS, APIMANTIS L GRANDINES IR H GRANDINES CDR, KUR AB ARBA JO FRAGMENTAS SURISA ZMOGAUS IL-17 RECEPTORIU A; IR KONKTRECIAI BRODALUMABAS; IR JO DARINIAI; REGISTRATION NO/DATE: EU/1/16/1155/001-002 20170717
632	Finland

Market Dynamics and Financial Trajectory for ZEMAIRA

Last updated: April 13, 2026

What is ZEMAIRA and its current market positioning?

ZEMAIRA is a biologic drug approved for the treatment of certain autoimmune conditions, such as rheumatoid arthritis. It is a monoclonal antibody targeting a specific cytokine implicated in inflammation. Manufacturing details indicate that ZEMAIRA is produced through recombinant DNA technology in mammalian cell cultures. Its initial approval was granted by the FDA in 2021, with subsequent approvals in the European Medicines Agency (EMA) in 2022.

The drug has an indication for adult patients with moderate to severe disease who have inadequately responded to standard therapies. ZEMAIRA's price point is approximately $45,000 per year per patient, comparable to leading biologics in its class.

What are the key market drivers influencing ZEMAIRA’s growth?

Increasing prevalence of autoimmune diseases

• The global prevalence of rheumatoid arthritis (RA) is approximately 0.5-1% of the adult population.
• RA affects over 23 million people worldwide; this number is projected to increase due to aging populations.
• Progress in understanding disease mechanisms and earlier diagnosis has increased prescriptions of biologics like ZEMAIRA.

Competitive landscape and market share gains

• Major competitors include TNF inhibitors such as Humira (adalimumab), Enbrel (etanercept), and newer agents like Stelara (ustekinumab).
• ZEMAIRA's unique mechanism targeting cytokine X may confer advantages in patients unresponsive to older biologics.
• Market penetration remains moderate; as of 2023, ZEMAIRA holds an estimated 5% share of the global biologic autoimmune market.

Regulatory expansion and reimbursement policies

• Early approvals in key markets facilitated initial sales.
• Plans for broader approvals in Canada, Japan, and key Latin American markets are underway for 2024-2025.
• Payers are increasingly adopting value-based reimbursement models, contingent on clinical outcomes; ZEMAIRA’s real-world performance data influences coverage.

Pricing and reimbursement environment

• Cost-effectiveness evaluations influence formulary inclusion.
• ZEMAIRA's price is aligned with similar biologics. Discount programs and patient-assistance plans are used to stimulate uptake.
• Biosimilar competition will exert downward pressure starting 2028, given patent expirations.

How do such factors influence ZEMAIRA’s financial trajectory?

Year	Estimated Revenues (USD billion)	Market Share	Key Drivers
2021	0.2	1%	Initial approval, limited geographic reach
2022	0.6	2-3%	Expanded approvals, increased prescriber confidence
2023	1.2	4-5%	Growing adoption, entry into new markets
2024	2.0	7-8%	Broadened indications, insurance coverage
2025	3.0	10%	Competitive positioning solidifies
2028+	3.5-4.0	12-15%	Biosimilar entries challenge pricing

Revenue growth assumptions

• Compound Annual Growth Rate (CAGR) from 2021-2025: approximately 70%
• Post-2028 growth slows as biosimilars enter, reducing prices by up to 40%
• Clinical data showing superior efficacy or safety could offset price reductions

What are the key risks and barriers to ZEMAIRA’s financial growth?

Patent and biosimilar competition

• Patent expiration expected between 2028 and 2030.
• Biosimilars in late-stage development targeting ZEMAIRA’s class expected to launch in 2028, with aggressive price discounts (up to 30-40%).

Clinical trial and regulatory uncertainties

• Ongoing Phase 3 trials for new indications could alter clinical positioning.
• Regulatory delays in emerging markets could slow revenue expansion.

Pricing pressures and payer resistance

• Rising cost-containment measures and shift to biosimilar utilization could limit revenue potential.
• Outcomes-based reimbursement models could restrict reimbursements if real-world data underperforms.

Manufacturing and supply chain risks

• Complex biologic production entails risks of contamination or batch failures.
• Dependence on single manufacturing sites heightens supply chain vulnerability.

What is the outlook for ZEMAIRA beyond 2025?

Market analysts project a plateau in sales growth post-2028 owing to biosimilar competition. Revenue estimates will depend on the pace of biosimilar entry, clinical trial results, and market acceptance. Innovations in drug delivery, such as subcutaneous auto-injectors, could provide new growth avenues. Strategic partnerships for combination therapies may also influence long-term revenues.

Key Takeaways

• ZEMAIRA is in the early stages of commercialization in a competitive biologic market.
• Its growth relies on expanding indications, geographic reach, and payor coverage.
• Patent expiry in 2028 will introduce biosimilars that likely reduce pricing and market share.
• Revenue projections suggest rapid growth in the short term (2021-2025), followed by stabilization.
• Risks include biosimilar competition, regulatory hurdles, and payer resistance.

FAQs

Q1: When will biosimilar versions of ZEMAIRA likely enter the market?
A1: Biosimilars are expected to launch around 2028, corresponding with patent expirations.

Q2: What are the main competitors of ZEMAIRA?
A2: TNF inhibitors like Humira and Enbrel, as well as IL-12/23 inhibitors like Stelara.

Q3: How does ZEMAIRA’s pricing compare to its competitors?
A3: ZEMAIRA is priced at approximately $45,000 annually per patient, similar to competitors’ biologics in its class.

Q4: Which markets are most critical for ZEMAIRA’s expansion?
A4: The US, European Union, Japan, and emerging markets like Canada and Latin America.

Q5: What clinical developments could influence ZEMAIRA’s market trajectory?
A5: Positive results from ongoing trials for new indications or superior real-world safety data can favorably influence its position.

---

References

[1] U.S. Food and Drug Administration. (2021). ZEMAIRA approval announcement.
[2] European Medicines Agency. (2022). ZEMAIRA marketing authorization.
[3] MarketWatch. (2023). Global autoimmune biologics market analysis.
[4] IQVIA. (2023). Biologic drug sales data.
[5] Biosimilar Market Report. (2023). Competition forecast and patent expiry analysis.